Real-world evaluation of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: A nationwide retrospective cohort study on behalf of the HS-SIDeMaST task force - Supplementary Materials
Description
Supplementary material Supplementary Material 1: Statistical methods Supplementary Material 2 - Table 1: Data stratified according to bimekizumab dose regimen Supplementary Material 3 - Table 2: Data stratified according to bimekizumab bio-naïve status Supplementary Material 4 - Figure 1: A 67-year-old woman with long-standing hidradenitis suppurativa, refractory to adalimumab, was switched to bimekizumab. (A) (C) show the baseline clinical presentation prior to bimekizumab initiation, with numerous draining fistulous lesions and severe skin pain. (B) (D) demonstrate the marked clinical improvement achieved after 36 weeks of treatment, characterised by a substantial reduction in purulent discharge and an overall improvement in patient-reported quality of life scores.